10th Jan 2025 16:07
Poolbeg Pharma PLC - London-based clinical stage biopharmaceutical firm - Updates on Gilead Sciences Inc's intentions regarding potential Hookipa Pharma Inc combination. Notes its intention to vote in line with the board of Hookipa in the instance of a formal offer and that it will participate in the proposed concurrent fundraise in an amount up to USD8.7 million. Says this is consistent with its existing contractual obligations. Hookipa intends to fundraise up to approximately USD30 million. Gilead currently owns a 19% stake in Hookipa. Poolbeg notes that all combination discussions have been non-binding in nature with no certainty present that a formal offer will be made.
Current stock price: 5.40 pence, down 3.6% on Friday afternoon in London
12-month change: down 45%
By Christopher Ward, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.